These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25828465)

  • 21. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
    Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint inhibition for advanced mucosal melanoma.
    Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
    Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
    Aleksova J; Lau PK; Soldatos G; McArthur G
    BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27881588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
    Hanna KS
    Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
    Chae YK; Chiec L; Mohindra N; Gentzler R; Patel J; Giles F
    Cancer Immunol Immunother; 2017 Jan; 66(1):25-32. PubMed ID: 27761609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
    Wen X; Wang Y; Ding Y; Li D; Li J; Guo Y; Peng R; Zhao J; Zhang X; Zhang XS
    Melanoma Res; 2016 Jun; 26(3):284-9. PubMed ID: 27116334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
    Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
    Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
    JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A; Haddox C; Block M; Kudva YC
    BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
    Escandon J; Peacock S; Trabolsi A; Thomas DB; Layka A; Lutzky J
    J Immunother Cancer; 2017; 5():3. PubMed ID: 28105370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.